|
DESIGN AND FORMULATION OF THERMOREVERSIBLE HYDROGEL CONTAINING CAPECITABINE AS CONTROLLED RELEASE DOSAGE FORM TO TREAT CANCER.
|
|
| Author:
|
HARSH VARIA, DR. RAJESH K.S
|
| Abstract:
|
The purpose of present research work was to design and formulation of capecitabine controlled release dosage form
to achieve a prolonged therapeutic effect with constantly releasing medication over an extended period of time by
administration of a single dose. The present study aims to treat colorectal cancer with improved patient compliance.
The selected drug, capecitabine is designed to release therapeutic concentration over a long period of time and
termed as controlled release dosage form. Capecitabine is readily absorbed from gastrointestinal tract. Hence
controlled release delivers maximum drug in colon lowering dosing frequency. Procured drug was identified as
Capecitabine by solubility study, melting point study, FT-IR study and calibration curve development.
Thermoreversible hydrogel containing capecitabine as a drug, thermoreversible polymer (PF-127) and viscosity
enhancing agent (HPMC E-50 LV) were prepared by cold method. The optimization of formulations was performed by
32 factorial design using Design Expert 9.0.4 software. The formulations were evaluated for visual appearance, clarity,
gelling capacity, pH, gelling temperature, viscosity, drug content and in-vitro release study, which shown satisfactory
results. The results of tests of parenteral formulations indicated that they were free from particulate matters and
sterilized completely. The results of stability study indicated that there was no significant change in gelling
temperature, viscosity and in-vitro drug release after one month. Thus, thermoreversible hydrogel was successfully
prepared and evaluated to provide better prospects for parenteral delivery of capecitabine in treatment of colorectal
cancer.
|
| Keyword:
|
Thermoreversible hydrogel, Colorectal cancer, Capecitabine
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2019.11.01.034
|
| Download:
|
Request For Article
|
|
|